天津医药

• 论著 • 上一篇    下一篇

氟伐他汀联合普罗布考对急性冠脉综合征患者血脂及血清超敏-C反应蛋白水平的影响

许振坤1,姚朱华2,王佩显3,4,曹月娟5,李永斌2   

  1. 1. 天津医科大学研究生院
    2. 天津市人民医院心内科
    3. 天津医科大学总医院
    4.
    5. 天津市胸科医院
  • 收稿日期:2011-07-22 修回日期:2011-12-27 出版日期:2012-06-15 发布日期:2012-06-15
  • 通讯作者: 姚朱华

The Effect of Fluvastatin-Probucol Combined Therapy on Levels of Serum Lipids and high sensitive C-reactive protein in Patients with Acute Coronary Syndrome

2,2,CAO Yue-Juan Yong-Bin LI   

  • Received:2011-07-22 Revised:2011-12-27 Published:2012-06-15 Online:2012-06-15

PDF (PC)

2209

摘要： 摘要 目的：探讨氟伐他汀联合普罗布考对急性冠脉综合征(ACS)患者血脂及血清超敏C-反应蛋白(hs-CRP)水平的影响。方法：收集ACS住院患者60例，随机分为A、B、C三组，每组各20例，A组给予氟伐他汀40 mg，1次/晚；B组给予氟伐他汀80 mg，1次/晚；C组给予氟伐他汀40 mg，1次/晚，并加用普罗布考250 mg，2次/天。三组患者均于治疗前清晨空腹取血，测定hs-CRP和血脂水平，包括总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)。给予相应药物治疗并门诊随访观察3个月后复查上述各项化验指标。结果：治疗前3组间各项血脂指标及hs-CRP水平差异均无统计学意义(P>0.05)。治疗后C组血脂指标和hs-CRP水平较A组均低(P<0.05)，TC及HDL-C水平较B组均低(P<0.05)，而TG及LDL-C水平与B组比较差异无统计学意义(P>0.05)。治疗前后C、B两组中TC、LDL-C水平显著降低(P<0.01)，且C组中TG水平也有降低(P<0.01)；各组hs-CRP水平均有降低(P<0.05)，而以C组降低最为明显(P<0.01)。结论：氟伐他汀联合普罗布考或大剂量氟伐他汀均能明显降低ACS患者血脂及hs-CPR水平，尤以氟伐他汀联合普罗布考效果更为显著。

关键词: 氟伐他汀, 普罗布考, 急性冠脉综合症, 血脂, 超敏C-反应蛋白

Abstract: Abstract Objective: To evaluate the effect of fluvastatin-probucol combined therapy on levels of serum lipid and hs-CRP in patients with acute coronary syndrome. Methods: A total of 60 patients with acute coronary syndrome were randomly divided into three groups, 20 patients in each group. The patients of group A were taken fluvastatin 40mg/d; the patients of group B were taken fluvastatin 80mg/d; and the patients of group C were taken fluvastatin 40mg/d and 250 mg of probucol twice a day. The serum levels of total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) and hs-CRP were examined before treatment. All of them were detected again after 3 months of treatment. Results: There were no significant differences in the levels of serum lipid and hs-CRP before treatment among three groups (P>0.05). After the 3 months follow-up, the levels of serum lipid and hs-CRP in group C were lower than group A (P<0.05); the levels of TC and HDL-C were lower than group B (P<0.05). There were no differences in the levels of TG and LDL-C between C and B groups (P>0.05). Compared with the pretreatment values, the levels of TC and LDL-C in group B and C were significantly decreased after the therapy of 3 months (P<0.01) and the level of TG in group C was also reduced (P<0.05); the level of hs-CRP was decreased after treatment in each group (P<0.05), especially in the group C (P<0.01). Conclusion: Combined treatment by fluvastatin and probucol or single high-dose fluvastatin therapy has intensive effect on lowing serum lipid and hs-CRP in ACS patiants. Especially, the combined theatment could further strengthen the efficacy.

Key words: Fluvastatin, Probucol, acute coronary syndrome, serum lipids, high sensitivity C-reactive protein